evaluated the efficacy of adalimumab as a primary outcome variable in patients with fistulizing CD. However, the effect of adalimumab on Crohn's perianal fistula has been reported as a secondary endpoint in three large, multicenter, doubleblind, placebo-controlled trials. 7 Currently, there are no head-to-head comparison trials with infliximab and adalimumab. An observational cohort study involving 327 patients (183 infliximab and 144 adalimumab) reported that both Perianal fistula complicating CD is common with up to 90% in patients with rectal involvement. Of importance, perianal disease is more commonly detected in East Asia, involving 58.8% of CD patients in Guangdong (China), 30.3% in Hong Kong, and 33.3% of pediatric and 43.1% of adult patients in Korea. 1, 2 Treatment goals for perianal fistula are reduction of abscess drainage and symptoms, and ultimately resolution of fistula discharge, improvement in quality of life, with preservation of continence, fistula healing, and avoidance of proctectomy and a stoma. 3 The treatment of perianal fistula should be individualized according to fistula location, presence of abscess, and disease activity, and multidisciplinary approaches are helpful, especially in cases of both medical and surgical treatments are required. www.irjournal.org anti-TNF agents showed similar response characteristics in CD patients. 8 In the current issue, Ji and Takano 9 reported the clinical efficacy of adalimumab, and compared the results with those for infliximab in CD patients with perianal fistula. They enrolled 47 perianal CD patients treated with either infliximab (n=31) or adalimumab (n=16). Of 26 patients with a simple fistula (55%), 17 were in the infliximab group and nine in the adalimumab group. The cumulative rate of fistula recurrence/aggravation was 37.5% in the adalimumab group and 16.1% in the infliximab group at 2 years after treatment. They found that seton placement was an independent risk factor for recurrence/aggravation of the fistula tract. Patients with a complex fistula who underwent seton placement were more likely to experience recurrence, but neither infliximab nor adalimumab influenced the clinical course. This study is meaningful in that the clinical efficacy of two anti-TNF agents was assessed in perianal fistula patients. However, this small retrospective study has several limitations. Two groups were enrolled at different times in the infliximab group between 2005 and 2010, and in the adalimumab group between 2010 and 2012. More than 50% had a simple fistula, which can be managed effectively with drainage and antibiotics. In addition, only nine patients received immunomodulators, which had a beneficial effect, especially in those on infliximab.
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Optimal treatment guidelines for fistulizing CD are needed; however, their development may be difficult because of diagnostic and treatment complexity, and the fact that high-quality clinical data for fistulizing CD are lacking. 4 Both infliximab and adalimumab can be used for perianal fistulas in CD, with consideration of the clinical setting and patient preferences, based on their similar efficacy. 9 However, combinations of anti-TNF agents with antibiotics or immunomodulators resulted in a better response; therefore, further studies with use of combined medications are warranted.
